Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Icagen (Nasdaq: ICGN) says it has sold patent rights to a gene linked to eye disorders to a Florida firm for $1 million.

AGTC, which is based in Florida, wants to use the gene as a potential treatment for sever daytime blindness called Achromatopsia.

Icagan said it retains rights to other therapeutics linked to the gene.

Get the latest news alerts: at Twitter